Tweaking the pirfenidone molecule yields an evidently effective but less toxic antifibrotic drug, investigators say.

Patients reported that side effects often impacted their quality of life (QOL). However, most patients said their treatment ...

Nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B) with antifibrotic and immunomodulatory effects, a ...

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of ...

Mortality rates were also concerning, with IPF-related deaths at 13.4% for pirfenidone and 7.2% for nintedanib, while all-cause mortality was 20.1% for pirfenidone and 16.6% for nintedanib.

Discover comprehensive details about Pirfenidone, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

The trial will evaluate pirfenidone capsules for the treatment of radiation-induced lung injury (RILI), with or without immune-related pneumonitis (CIP). This regulatory milestone marks the ...

placebo in IPF patients. Both deupirfenidone doses were well-tolerated, with similar GI-related adverse event rates to pirfenidone 801 mg TID. Unlock your all-in-one trading dashboard with real ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with ...

"A study with global reach, tailored to examine each patient's most severe symptoms, has the potential to bring hope to people well beyond Canada and the U.S." The trial will examine whether ...